Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory MSS metastatic colorectal cancer
Arndt Vogel, Managing Senior Consultant at Hannover Medical School, shared an article by Annie Xiao on X:
“Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory MSS metastatic colorectal cancer in Oncology Advance.
- phs-1, 39 pts.
- ORR 36%, mPFS 5 & mOS 27.5 mo.
- 3-yr PFS rate 19.3 %.
- some long-term responders, 3 w/ potential cure, we need a biomarker…”
Authors: Annie Xiao, et al.
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023